Method for inducing tailored pluripotent stem cells using extract of plant stem cells or plant dedifferentiated stem cells, and pluripotent stem cells produced by means of the method

US9976118B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-9976118-B2
Application numberUS-201414762773-A
CountryUS
Kind codeB2
Filing dateJan 28, 2014
Priority dateJan 30, 2013
Publication dateMay 22, 2018
Grant dateMay 22, 2018

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

A method for inducing tailored pluripotent stem cells by reprogramming differentiated cells of an adult by using an extract of plant stem cells and plant dedifferentiated stem cells (callus); pluripotent stem cells produced by means of the method; and a cell therapy agent comprising the pluripotent stem cells are disclosed. It is possible to overcome ethical problems since eggs are not used in the making of pluripotent stem cells having abilities like embryonic stem cells. It is possible to produce pluripotent stem cells of ensured safety because a plant stem cell extract which above all has been verified to be harmless to the body is used. It is possible to develop an immunocompatible cell therapy agent tailored to different individuals.

First claim

Opening claim text (preview).

The invention claimed is: 1. A method of producing induced stem cells, comprising: pre-treating human dermal fibroblasts with a membrane permeability-promoting material; contacting a Sequoia callus extract with the pre-treated human dermal fibroblasts such that at least part of the Sequoia callus extract is permeated into the pre-treated human dermal fibroblasts, which provides modified human cells containing at least part of the Sequoia callus extract; culturing, in a culture medium, the modified human cells containing at least part of the Sequoia callus extract, which produces induced stem cells expressing Nanog and Oct-3/4; and subsequently collecting at least part of the induced stem cells expressing Nanog and Oct-3/4. 2. The method of claim 1 , wherein the Sequoia callus extract comprises proteins, lipids, sugars and acids of callus of Sequoia. 3. The method of claim 1 , wherein the method further comprises mixing the Sequoia callus extract with the culture medium before contacting the Sequoia callus extract with the human dermal fibroblasts. 4. The method of claim 1 , wherein the Sequoia callus extract contacts the pre-treated human dermal fibroblasts in the form of suspension in water and has a concentration of 100 ug/ml to 1 mg/ml. 5. The method of claim 4 , wherein the concentration is 500 ug/ml. 6. The method of claim 1 , wherein the Sequoia callus extract is in powder. 7. The method of claim 6 , wherein the powder of the Sequoia callus extract is dissolved in water before contacting the pre-treated human dermal fibroblasts. 8. The method of claim 1 , wherein the membrane permeability-promoting material includes streptolysin O. 9. The method of claim 1 , wherein the membrane permeability-promoting material includes digitonin. 10. The method of claim 1 , wherein culturing comprises transferring the modified human cells containing at least part of the Sequoia callus extract onto a surface of feeder cells. 11. The method of claim 10 , wherein the feeder cells comprise STO cells. 12. The method of claim 10 , wherein the culture medium comprises a Knockout serum replacement. 13. The method of claim 10 , wherein subsequent to transferring, the modified human cells containing at least part of the Sequoia callus extract are cultured on the surface of the feeder cells, wherein the culture medium comprises a Knockout serum replacement, wherein culturing in the culture medium is performed subsequent to culturing on the surface of the feeder cells. 14. The method of claim 1 , wherein the culture medium comprises a Knockout serum replacement.

Assignees

Inventors

Classifications

  • Products or compounds obtained by genetic engineering · CPC title

  • C12N5/04Primary

    Plant cells or tissues {(culture media C12N5/0025)} · CPC title

  • Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof · CPC title

  • from algae, fungi, lichens or plants; from derivatives thereof · CPC title

  • Artificially induced pluripotent stem cells, e.g. iPS · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US9976118B2 cover?
A method for inducing tailored pluripotent stem cells by reprogramming differentiated cells of an adult by using an extract of plant stem cells and plant dedifferentiated stem cells (callus); pluripotent stem cells produced by means of the method; and a cell therapy agent comprising the pluripotent stem cells are disclosed. It is possible to overcome ethical problems since eggs are not used in …
Who is the assignee on this patent?
Snu R&Db Foundation
What technology area does this patent fall under?
Primary CPC classification C12N5/04. Mapped technology areas include Chemistry & Metallurgy.
When was this patent published?
Publication date Tue May 22 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).